Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA panel to review Medtronic’s InFuse

This article was originally published in The Gray Sheet

Executive Summary

Bone graft for oral maxillofacial procedures will go before agency's Dental Products Panel Nov. 9 in Gaithersburg, Md., according to the Oct. 26 Federal Register. Infuse contains the recombinant human bone morphogenetic protein rhBMP-2 - a "genetically engineered version of a naturally occurring protein ... capable of initiating bone growth," Medtronic says. InFuse also is being studied under an investigational device exemption for use in cervical spinal fusion (1"The Gray Sheet" Oct. 16, 2006, In Brief)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT024157

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel